Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

By V. Verwaal, S. van Ruth, E. de Bree, Gooike W van Sloothen, H. van Tinteren, H. Boot, F. Zoetmulder. Journal of Clinical Oncology, 2003

2,017 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. (2009, methodology): “The procedure has been performed for more than 10 years at the Gustave Roussy Institute, even though its efficacy had not been proven in a randomized trial until 2003.(3) The usual main argument against HIPEC is the stringent selection of patients.”
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer (2008, background): “The first complete randomized trial was published in 2003.(13) Although it was based on a relatively small number of patients, it was sufficient to reliably detect and find a difference in median survival.”
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. (2004, result): “Recently, preliminary results of a phase III study of IPCH combined with mitomycin was reported by the Netherlands Center Institute.(21) Patients with known colorectal carcinomatosis were preoperatively randomly assigned to standard treatment with palliative surgery followed by systemic fluorouracil”